» Articles » PMID: 29109792

MiR-205/YAP1 in Activated Fibroblasts of Breast Tumor Promotes VEGF-independent Angiogenesis Through STAT3 Signaling

Overview
Journal Theranostics
Date 2017 Nov 8
PMID 29109792
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor microenvironment contributes to tumor angiogenesis. However, the role of the activated cancer associated-fibroblasts (CAFs) in angiogenesis is still unclear. Here we report that miR-205/YAP1 signaling in the activated stromal fibroblasts plays a critical role in VEGF-independent angiogenesis in breast tumor. miR-205 expression was assessed by quantitative real-time polymerase chain reaction (qRT-PCR); YAP1 expression by qRT-PCR, western blotting and immunohistochemistry; IL11 and IL15 expression by qRT-PCR, western blotting and ELISA. Tube formation and three-dimensioned sprouting assays , and orthotopic Xenografts were conducted as angiogenesis experiments. The mechanism of miR-205/YAP1-mediated tumor angiogenesis was analyzed via overexpression and shRNA, siRNA, or antibody neutralization experiments in combination with anti-VEGF antibody or Axitinib. miR-205/YAP1 signaling axis activates breast normal fibroblasts (NFs) into CAFs, promotes tubule formation and sprouting of Human Umbilical Vein Endothelial Cells (HUVECs). Rescue of miR-205 in CAFs blunts angiogenesis processes. YAP1, a target of miR-205, does not regulate VEGF expression but specifically enhances IL11 and IL15 expressions, maintaining tumor angiogenesis even in the presence of Axitinib or after exhaustion of VEGF by neutralizing VEGF antibody. IL11 and IL15 released from CAFs activate STAT3 signaling in HUVECs. Blockage of IL11 and IL15 expression in CAFs results in the inactivation of STAT3-signaling in HUVECs and repression of the CAF-induced angiogenesis. The blunt angiogenesis halts the invasion and metastasis of breast cancer cells . These results provide a novel insight into breast CAF-induced tumor angiogenesis in a VEGF-independent manner.

Citing Articles

ETHE1 dampens colorectal cancer angiogenesis by promoting TC45 Dephosphorylation of STAT3 to inhibit VEGF-A expression.

She X, Xu J, Zhang H, Yu C, Rao Z, Zhang J Cell Death Dis. 2024; 15(8):631.

PMID: 39198402 PMC: 11358511. DOI: 10.1038/s41419-024-07021-w.


Development of 42 marker panel for in-depth study of cancer associated fibroblast niches in breast cancer using imaging mass cytometry.

Rogenes H, Finne K, Winge I, Akslen L, Ostman A, Milosevic V Front Immunol. 2024; 15:1325191.

PMID: 38711512 PMC: 11070582. DOI: 10.3389/fimmu.2024.1325191.


CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance.

Coursier D, Calvo F Cell Oncol (Dordr). 2024; 47(4):1091-1112.

PMID: 38453816 PMC: 11322395. DOI: 10.1007/s13402-024-00931-z.


The role of transcription factors in the crosstalk between cancer-associated fibroblasts and tumor cells.

Zhang X, Zhang M, Sun H, Wang X, Wang X, Sheng W J Adv Res. 2024; 67():121-132.

PMID: 38309692 PMC: 11725164. DOI: 10.1016/j.jare.2024.01.033.


A novel prognostic predictor of immune microenvironment and therapeutic response in clear cell renal cell carcinoma based on angiogenesis-immune-related gene signature.

Ding G, Wang T, Tang G, Zou Q, Wu G, Wu J Heliyon. 2024; 10(1):e23503.

PMID: 38170124 PMC: 10758882. DOI: 10.1016/j.heliyon.2023.e23503.


References
1.
Guo S, Tao S, Yin W, Qi X, Yuan T, Zhang C . Exosomes derived from platelet-rich plasma promote the re-epithelization of chronic cutaneous wounds via activation of YAP in a diabetic rat model. Theranostics. 2017; 7(1):81-96. PMC: 5196887. DOI: 10.7150/thno.16803. View

2.
Torok S, Rezeli M, Kelemen O, Vegvari A, Watanabe K, Sugihara Y . Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. Theranostics. 2017; 7(2):400-412. PMC: 5197073. DOI: 10.7150/thno.16767. View

3.
Pan D, Schmieder A, Wang K, Yang X, Senpan A, Cui G . Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles. Theranostics. 2014; 4(6):565-78. PMC: 3982128. DOI: 10.7150/thno.7581. View

4.
Peng Q, Zhao L, Hou Y, Sun Y, Wang L, Luo H . Biological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancer. PLoS One. 2013; 8(4):e60321. PMC: 3618271. DOI: 10.1371/journal.pone.0060321. View

5.
Claesson-Welsh L, Welsh M . VEGFA and tumour angiogenesis. J Intern Med. 2012; 273(2):114-27. DOI: 10.1111/joim.12019. View